APUS Stock Chart & Stats
$3.87
$0.64(11.33%)
At close: 4:00 PM EDT
$3.87
$0.64(11.33%)
Day’s Range― - ―
52-Week Range$1.51 - $59.70
Previous CloseN/A
Volume10.74K
Average Volume (3M)4.35M
Market Cap
$4.86M
Enterprise Value$10.20T
Total Cash (Recent Filing)$278.37K
Total Debt (Recent Filing)$14.58M
Price to Earnings (P/E)―
Beta1.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-49.29
Shares Outstanding1,509,118
10 Day Avg. Volume12,802,602
30 Day Avg. Volume4,346,351
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap2.10M
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-508.95M
Enterprise Value/Ebitda-189.55K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Apimeds Pharmaceuticals US, Inc. News
APUS FAQ
What was Apimeds Pharmaceuticals US, Inc.’s price range in the past 12 months?
Apimeds Pharmaceuticals US, Inc. lowest stock price was $1.51 and its highest was $59.70 in the past 12 months.
What is Apimeds Pharmaceuticals US, Inc.’s market cap?
Apimeds Pharmaceuticals US, Inc.’s market cap is $4.86M.
When is Apimeds Pharmaceuticals US, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Apimeds Pharmaceuticals US, Inc.’s earnings last quarter?
Currently, no data Available
Is Apimeds Pharmaceuticals US, Inc. overvalued?
According to Wall Street analysts Apimeds Pharmaceuticals US, Inc.’s price is currently Overvalued.
Does Apimeds Pharmaceuticals US, Inc. pay dividends?
Apimeds Pharmaceuticals US, Inc. does not currently pay dividends.
What is Apimeds Pharmaceuticals US, Inc.’s EPS estimate?
Apimeds Pharmaceuticals US, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apimeds Pharmaceuticals US, Inc. have?
Apimeds Pharmaceuticals US, Inc. has 1,509,118 shares outstanding.
What happened to Apimeds Pharmaceuticals US, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Apimeds Pharmaceuticals US, Inc.?
Currently, no hedge funds are holding shares in APUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Technical Analysis
Sonoma Pharmaceuticals
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
cbdMD
―
Biofrontera
―
Ownership Overview
11.08%
Insiders
0.86% Mutual Funds
1.82% Other Institutional Investors
85.91% Public Companies and
Individual Investors